Vaccibody AS announces inclusion of first patient in phase IIa study
(23.03.17)

| News

Vaccibody AS announces vaccination of first patient in its phase IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix. Read more

Sarsia Seed